TP53 and cervical carcinoma: Collectively, our in vivo results were in agreement with our in vitro studies validating the 6G induced p53 reactivation though proteasomal inhibition in cervical cancer cells (Figure 6I) along with its lack of toxicity in the experimental animal model.